The total number of US institutions partnering with Ximbio rises to 30!
Ximbio has experienced a rapid expansion in the number of partnerships it has with US institutions, with 10 institutions signing new agreements with Ximbio during the last six months. Some of our latest US partners include:
Johns Hopkins University - It has over 1,310 research, educational or related activities across more than 150 countries and spent $353M last year on overseas research, educational, or related activities.
Howard Hughes Medical Institute (HHMI) - One of the largest private funding organizations for biological and medical research in the United States.
Rutgers University - One of the top US public universities spending $712 million annually on research and development. It has over 300 research centres and institutions across the state of New Jersey.
University of Iowa - In 2018, it filed 152 patent applications and received 2,477 research grants and contracts.
Versiti Blood Research Institute – It brings together outstanding minds with unparalleled experience in transfusion medicine, transplantation, stem cells and cellular therapies and oncology and genomics. It focuses its research on a variety of areas including Molecular Biology, thrombosis, viral vectors, hybridomas and protein chemistry.
The US life sciences industry has been a major focus for Ximbio over the past few years, with significant investment taking place to both expand and develop the US team. New recruits include Jonathan Viola and Helena Lucente, both of whom are focussed on managing Ximbio’s ever-growing reagent portfolio and maintaining our close working partnerships.
The growth in the number of US institutes partnering with Ximbio is also fantastic news for all of Ximbio’s current partners. This is because TTOs and researchers now have a larger opportunity to build their international profile, through the increased number of visitors accessing Ximbio’s portfolio. Most importantly the increase in the number of US partners provides a larger pool of reagents for you to access. Some of the newest reagents added to the Ximbio portfolio from the US institutions include:
- Anti-O-GlcNAc (CTD110.6) monoclonal antibody - The β-O-linked N-acetylglucosamine (O-GlcNAc) antibody recognizes glycosylation, a post-translational modification, which occurs on serine and threonine residues of proteins in the nuclear and cytoplasmic compartments.
- Anti-phospho Sam68, Ser113/117 Polyclonal Antibody - Sam68 (KHDRBS1 also known as KH domain-containing, RNA-binding, signal transduction-associated protein 1) is a RNA binding protein that binds to U(U/A)AA direct repeats to regulate RNA splicing, transcription, RNA metabolism, signal transduction, the cell cycle and apoptosis.
- FluoDot 28-425 - Protein-based fluorescent nanoparticles with a covalently-linked lipid layer. FluoDots have multiple applications such as cancer drug delivery, cell imaging, solar cell coating materials, protease detection and BioLEDs.
- jRCaMP1 plasmids - The single-wavelength red genetically encoded calcium indicator (GECI), based mRuby (jRCaMP1a, b), with sensitivity comparable to the GFP-based GCaMP6.
- Anti-F. tularensis LVS sucB [195] Antibody - This mouse IgG2a monoclonal is reactive against both F. tularensis LVS and F. tularensis SchuS4 protein sucB.
- StarD5 Knock-out Mouse - The StarD5 protein has been knocked out in this mouse to help facilitate the study of the effects of disrupting pathways associated with cholesterol and the resulting pathological conditions.
- PC3-ML-Luciferase Prostate Cancer Cell Line - These luciferase stable PC3 cells are useful for non-invasive visualisations in in vitro experiments. This cell line is also useful in the research of prostate cancer as the androgen receptor (AR) helps prostate cancer cells to survive and is a target for many anti cancer research studies focusing on inhibition.